L. Austin Doyle

6.2k total citations · 2 hit papers
39 papers, 5.0k citations indexed

About

L. Austin Doyle is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, L. Austin Doyle has authored 39 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 19 papers in Molecular Biology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in L. Austin Doyle's work include Drug Transport and Resistance Mechanisms (20 papers), Pharmacological Effects and Toxicity Studies (10 papers) and Cancer therapeutics and mechanisms (8 papers). L. Austin Doyle is often cited by papers focused on Drug Transport and Resistance Mechanisms (20 papers), Pharmacological Effects and Toxicity Studies (10 papers) and Cancer therapeutics and mechanisms (8 papers). L. Austin Doyle collaborates with scholars based in United States, Canada and Japan. L. Austin Doyle's co-authors include Douglas D. Ross, Weidong Yang, Lynne V. Abruzzo, Arun K. Rishi, Tammy Krogmann, D D Ross, Lee M. Greenberger, Judith E. Karp, Sridhar K. Rabindran and Bret A. Hassel and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

L. Austin Doyle

39 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A multidrug resistance transporter from human MCF-7 breast cancer cells

1998 1.8k citations L. Austin Doyle, Weidong Yang et al. profile →
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

2003 880 citations L. Austin Doyle, Douglas D. Ross Oncogene profile →

Peers

Countries citing papers authored by L. Austin Doyle

Since Specialization

Citations

This map shows the geographic impact of L. Austin Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Austin Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Austin Doyle more than expected).

Fields of papers citing papers by L. Austin Doyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Austin Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Austin Doyle. The network helps show where L. Austin Doyle may publish in the future.

Co-authorship network of co-authors of L. Austin Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of L. Austin Doyle. A scholar is included among the top collaborators of L. Austin Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Austin Doyle. L. Austin Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients 2017 ·Clinical Cancer Research ·(unknown), Vijay Ivaturi, Jogarao Gobburu, Jacqueline M. Greer, L. Austin Doyle, James R. Wright, Judith E. Karp, Michelle A. Rudek	9
2	Muscle anabolism in advanced cancer: Is cachexia an immutable phenomenon? 2011 ·Journal of Clinical Oncology ·Carla M. Prado, Vickie E. Baracos, Tanios Bekaii‐Saab, L. Austin Doyle, Jessica Lieffers, Nina Esfandiari, Subhamay Ghosh, S. Antoun, Michael B. Sawyer	1
3	Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179 2009 ·Journal of Clinical Oncology ·Amit M. Oza, Christian Kollmannsberger, Hal W. Hirte, Stephen Welch, Lillian L. Siu, (unknown), (unknown), L. Austin Doyle, (unknown)	6
4	Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) breakdown → 2003 ·Oncogene ·L. Austin Doyle, Douglas D. Ross	880
5	Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis 2003 ·Molecular Pharmacology ·Takeo Nakanishi, L. Austin Doyle, Bret A. Hassel, (unknown), Kenneth S. Bauer, Suhlan Wu, David W. Pumplin, Hong‐Bin Fang, Douglas D. Ross	65
6	The ability of whole body FDG18 PET imaging to predict pathologic response to induction chemoradiotherapy in locally advanced esophageal cancer. A prospective phase II trial 2003 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Bruce R. Line, L. Austin Doyle, Mark J. Krasna	8
7	Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. 2003 ·PubMed ·Takeo Nakanishi, Judith E. Karp, Ming Tan, L. Austin Doyle, Todd Peters, Weidong Yang, David Wei, Douglas D. Ross	62
8	Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene 2001 ·Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression ·(unknown), Bret A. Hassel, L. Austin Doyle, Douglas D. Ross	180
9	Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells 2001 ·Biochemical and Biophysical Research Communications ·Shigeru Kawabata, (unknown), Ken Shiozawa, Kazuhiro Tsukamoto, Katsumi Nakatomi, Hiroshi Soda, Minoru Fukuda, Yoji Ikegami, Kazuyuki Sugahara, Yasuaki Yamada, Shimeru Kamihira, L. Austin Doyle, (unknown), Shigeru Kohno	198
10	Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines 1999 ·JNCI Journal of the National Cancer Institute ·D D Ross, Weidong Yang, Lynne V. Abruzzo, William S. Dalton, E Schneider, Hermann Lage, Manfred Dietel, Lee M. Greenberger, Susan P.C. Cole, L. Austin Doyle	284
11	Safe pulmonary resection after chemotherapy and high-dose thoracic radiation 1999 ·The Annals of Thoracic Surgery ·Joshua Sonett, Mark J. Krasna, Mohan Suntharalingam, (unknown), L. Austin Doyle, Rogério Lilenbaum, Ziv Gamliel	51
12	Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide 1997 ·International Journal of Cancer ·Román Pérez-Soler, Nouri Neamati, Yiyu Zou, Erasmus Schneider, L. Austin Doyle, Michael Andreeff, Waldemar Priebe, Yi‐He Ling	15
13	A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene 1997 ·Cancer Chemotherapy and Pharmacology ·(unknown), Mikio Oka, Minoru Fukuda, (unknown), Kôki Ikeda, Hiroshi Takatani, Kenji Terashi, Hiroshi Soda, Osamu Yano, Tsuyoshi Nakamura, L. Austin Doyle, Takashi Tsuruo, Shigeru Kohno	29
14	Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. 1996 ·PubMed ·D D Ross, L. Austin Doyle, CA Schiffer, (unknown), Caroline E. Grant, Susan P.C. Cole, R G Deeley, Weidong Yang, Yin Tong	39
15	Characterization of a 95 kilodalton membrane glycoprotein associated with multi‐drug resistance 1995 ·International Journal of Cancer ·L. Austin Doyle, (unknown), Weidong Yang, Douglas D. Ross	7
16	Expresssion of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells 1995 ·British Journal of Cancer ·L. Austin Doyle, (unknown), R N Sridhara, Antonio Tito Fojo, Scott H. Kaufmann, (unknown), CA Schiffer	28
17	Topoisomerase expression in cancer cell lines and clinical samples 1994 ·Cancer Chemotherapy and Pharmacology ·L. Austin Doyle	15
18	Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines 1991 ·Lung Cancer ·L. Austin Doyle, M Mabry, R. Stahel, Robert Waibel, Laura H. Goldstein	3
19	An adherent subline of a unique small-cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule. 1990 ·Journal of Clinical Investigation ·L. Austin Doyle, Michael Borges, (unknown), Anthony Elias, Takafumi Tomiyasu	30
20	Identification of conditioned medium proteins from human cancer cells adapted to serum-free conditions 1990 ·Analytical Biochemistry ·L. Austin Doyle, (unknown), (unknown), Frank Cuttitta	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact